• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Helius Medical Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    6/23/25 8:30:26 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HSDT alert in real time by email
    0001610853false00016108532025-06-232025-06-23

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 23, 2025

    Graphic

    HELIUS MEDICAL TECHNOLOGIES, INC.

    (Exact name of registrant as specified in its charter)

    ​

    -

    ​

    ​

    Delaware

    001-38445

    36-4787690

    (State or other jurisdiction

    of incorporation)

    (Commission File Number)

    (IRS Employer

    Identification No.)

    ​

    ​

    ​

    642 Newtown Yardley Road, Suite 100

    Newtown, PA

     

    18940

    (Address of principal executive offices)

     

    (Zip Code)

    ​

    Registrant’s telephone number, including area code: (215) 944-6100

    N/A

    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ​

    ​

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Title of each class

        

    Trading

    Symbol(s)

        

    Name of each exchange on which registered

    Class A Common Stock, $0.001 par value

    ​

    HSDT

    ​

    The Nasdaq Stock Market LLC

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Item 8.01Other Events.

    ​

    As previously disclosed, on March 31, 2025, Helius Medical Technologies, Inc. (the “Company”) received written notice Staff stating that the Company no longer complied with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”) for continued listing on The Nasdaq Stock Market LLC because the Company’s stockholders’ equity, as reported in the Company’s Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2024, had fallen below $2.5 million. The notice also indicates that the Company did not meet the alternative compliance standards. On April 1, 2025, the Company received an additional letter from Nasdaq notifying the Company that, following the hearing process, Nasdaq had granted the Company an extension, until June 30, 2025 to regain compliance with the Nasdaq Listing Rules, including the Stockholders’ Equity Requirement. Also, as previously disclosed, on June 6, 2025, the Company completed a public offering for net proceeds of approximately $8.1 million.

    ​

    To demonstrate compliance with the Continued Listing Standards, the Company is furnishing the attached unaudited interim consolidated balance sheet as of June 17, 2025 which gives effect to the public offering. As reflected in the attached unaudited balance sheet, the Company has stockholders’ equity of at least $2.5 million and therefore believes it satisfies Stockholders’ Equity Requirement. The Company awaits Nasdaq’s formal confirmation that the Company has evidenced compliance with the Stockholders’ Equity Rule and all other applicable criteria for continued listing on The Nasdaq Capital Market.

    ​

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

    ​

    Exhibit No.

        

    Description

    ​

    ​

    ​

    99.1

    ​

    Unaudited Interim Consolidated Balance Sheet, as of June 17, 2025.

    104

    ​

    Cover Page Interactive Data File (embedded within Inline XBRL document).

    ​

    ​

    ​

    ​

    2

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    HELIUS MEDICAL TECHNOLOGIES, INC.

    ​

    ​

    ​

    ​

    Dated: June 23, 2025

    ​

    By:

    /s/ Jeffrey S. Mathiesen

    ​

    ​

    ​

    Jeffrey S. Mathiesen

    ​

    ​

    ​

    Chief Financial Officer, Treasurer and Secretary

    ​

    ​

    ​

    3

    Get the next $HSDT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HSDT

    DatePrice TargetRatingAnalyst
    11/15/2021Outperform → Market Perform
    Noble Capital Markets
    More analyst ratings

    $HSDT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Helius Medical Technologies Announces Reverse Stock Split

      NEWTOWN, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-50 reverse split of its Class A common stock, par value $0.001 ("common stock"), effective at 5:00 pm Eastern time on June 30, 2025. Beginning on July 1, 2025, the Company's common stock will trade on The Nasdaq Capital Market on a split adjusted basis. At the Company's special meeting of stockholders on May 23, 2025, the stockholders approved a proposal to amend the Company's Certificate of Incorporation to effect a reverse s

      6/27/25 8:30:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device

      - CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19,160- NEWTOWN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an additional authorized claim for payment for the PoNS Device from CignaHealth. CignaHealth becomes the fifth major payer to authorize claims for payment for the PoNS Device

      6/16/25 7:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting

      -PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of full PoNSTEP study results expanded upon top line data previously reported- NEWTOWN, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Deborah Backus, PT, Ph.D., FACRM- Vice President of Research and Innovation at Atlanta's Shepard Center presented the positive results from the PoNS Therapeutic Experience Program, or

      6/12/25 6:59:59 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    SEC Filings

    See more
    • Helius Medical Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      7/7/25 5:02:35 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 424B5 filed by Helius Medical Technologies Inc.

      424B5 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      7/7/25 5:00:56 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      6/27/25 9:00:17 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Andreeff Dane bought $8,229 worth of shares (1,284 units at $6.41) (SEC Form 4) (Amendment)

      4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      2/15/24 4:06:00 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Andreeff Dane bought $40,475 worth of shares (5,000 units at $8.10) (SEC Form 4)

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      12/15/23 7:00:42 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Andreeff Dane bought $25,675 worth of shares (4,006 units at $6.41) (SEC Form 4)

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      12/4/23 8:30:12 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Helius Medical Tech downgraded by Noble Capital Markets

      Noble Capital Markets downgraded Helius Medical Tech from Outperform to Market Perform

      11/15/21 10:55:44 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Noble Capital Markets initiated coverage on Helius Medical with a new price target

      Noble Capital Markets initiated coverage of Helius Medical with a rating of Outperform and set a new price target of $20.00

      3/24/21 8:02:45 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LADENBURG THALM/SH SH initiated coverage on Helius Medical Technologies

      LADENBURG THALM/SH SH initiated coverage of Helius Medical Technologies with a rating of Buy

      2/12/21 8:21:57 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CFO and Treasurer Mathiesen Jeffrey S

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      7/3/25 8:00:26 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Favit-Van Pelt Antonella R.

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      7/3/25 8:00:28 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Walter Blane

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      7/3/25 8:00:24 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Financials

    Live finance-specific insights

    See more
    • Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device

      NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today provided updates on its efforts to achieve fair market access for its Portable Neuromodulation Stimulator (PoNS) device and announced plans to host a business update call today at 9:00am ET.   "We disagree with the proposed pricing for the PoNS Mouthpiece and are disappointed CMS has once again mapped the Controller pricing to a code for fundamentally different technology," said Dane Andreeff, Helius' President and Chief Executive Officer. "I

      11/18/24 8:01:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024

      NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date:Monday, Augus

      8/6/24 4:36:06 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024

      NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its first quarter 2024 financial results on Monday, May 13, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date: Monday, May 13, 2

      5/10/24 9:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Leadership Updates

    Live Leadership Updates

    See more
    • Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device

      -Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. "The recent reimbursement approvals from two major

      6/11/25 7:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting

      NEWTOWN, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced it will highlight the results of a new study confirming the therapeutic regimen and sustained efficacy of its Portable Neuromodulation Stimulator (PoNS®) device for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The event runs from May 28-31 at the Phoenix Convention Center in Phoenix. Deborah Backus, PT, Ph.D., FACRM – Vice President of Research and Innovation at Atlanta's Shepherd Center, one of six sit

      5/20/25 7:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies, Inc. Appoints Paul Buckman to its Board of Directors

      NEWTOWN, Pa., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the appointment of Paul Buckman to its Board of Directors, effective September 10, 2021. Mr. Buckman will serve as Chair of the Company's Audit Committee and as a member of its Compensation and Nominating & Governance Committees. "Paul is a highly accomplished executive with more than 30 years of experience in the medical device sector, including senior leadership positions at some of the most well-regarded companies in the industry," said Blane Walter, Chairman of Helius' Board of Directors. "I

      9/14/21 7:05:00 AM ET
      $HSDT
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Helius Medical Technologies Inc.

      SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

      11/8/24 5:12:24 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Helius Medical Technologies Inc.

      SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

      5/14/24 4:15:39 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Helius Medical Technologies Inc. (Amendment)

      SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

      2/13/24 7:09:07 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care